Pharmacovigilance failures tend to surface publicly only when something goes wrong. A delayed safety signal, an inspection finding or a post market correction can quickly escalate into reputational and financial consequences for drugmakers. Against that backdrop, shifting regional expectations are forcing companies to reconsider how local pharmacovigilance responsibilities are defined, resourced and monitored, especially for…